Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years

Nelson, Anita L.

doi:10.1080/17512433.2017.1341308

Cited by 13 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of EP due to IUD use is rare [ 1 , 6 ]. However, there are certain factors that increase a patient’s risk including pelvic inflammatory disease, sexually transmitted infection, endometriosis, migration of the levonorgestrel-releasing intrauterine system, age, scarring, previous pregnancies, appendectomy, prior fallopian tube surgery, and many others [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, Kyleena is one of the smallest and secretes the least amount of hormone. Due to the minimal hormonal secretion, small size, and long duration of use, Kyleena is becoming one of the more appealing options for patients interested in an IUD [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

“…Our research on the topic of hormonal IUDs and EPs emphasizes the rare nature of this case as data show pregnancies occur less than 1% of the time with IUD contraceptive use [ 6 ]. This case brings to light the potential risk of EP associated with Kyleena, even without any typical EP risk factors.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Ectopic Pregnancy Observed With Kyleena Intrauterine Device Use: A Case Report

Singer¹,

Melchor²,

Ripps³

et al. 2023

Cureus

View full text Add to dashboard Cite

Kyleena (levonorgestrel 19.5 mg), a type of intrauterine device (IUD), has an efficacy rate of 99% in preventing pregnancy. Because the overall failure rate of IUDs is low, ectopic pregnancy (EP) with IUD use is uncommon. This case reports an EP observed in a female with the Kyleena IUD in place. She had no known risk factors for an EP, which makes this case noteworthy. Ultrasound and surgery confirmed a 4 cm EP in the ampulla of the left fallopian tube. Insufficient evidence exists to conclude whether the Kyleena IUD has a higher risk of EP compared to other hormonal IUDs. As the Kyleena IUD becomes a more popular option for women in search of an effective contraceptive, patients and clinicians should be aware of this potential risk. Our case emphasizes that continued research on the prevalence of EP with Kyleena use is necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ectopic Pregnancy Observed With Kyleena Intrauterine Device Use: A Case Report

Singer¹,

Melchor²,

Ripps³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…It is licensed for HMB for up to 5 years. LNG-IUS 12 : Total content of 19.5 mg; LNG is initially released at a rate of 13 μg/day and has a duration of action of 5 years [ 62 ]. The device is not licensed for HMB.…”

Section: Levonorgestrel-releasing Intrauterine Systemsmentioning

confidence: 99%

Utility of the Levonorgestrel-Releasing Intrauterine System in the Treatment of Abnormal Uterine Bleeding and Dysmenorrhea: A Narrative Review

Bianchi

Guo

Habiba

et al. 2022

JCM

View full text Add to dashboard Cite

Introduction: We undertook a literature review of the use of levonorgestrel-releasing intrauterine devices when utilized for heavy menstrual bleeding and/or dysmenorrhea. Methods: A narrative review of articles in the Scopus and Medline databases was conducted. Results: A number of options exist for the management of both abnormal uterine bleeding (AUB) and dysmenorrhea, and evidence is accumulating that the insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) represents a useful option for their long-term treatment. The idea of using a progestogen released in utero was initially conceived to achieve long-term contraception, but it was quickly found that these systems could be utilized for a number of therapeutic applications. The first device to be made commercially available, Progestasert, was withdrawn from the market because, in the event of contraceptive failure, it caused a disproportionate percentage of extrauterine pregnancies. On the other hand, the LNG-IUS continues to be successfully utilized in its various variants, releasing 20, 13, or 8 μg/day. These devices have a respective duration of action of 7 (possibly 8), 5, and 3 years, and there exist versions of frameless systems affixed to the myometrium of the uterine fundus. In the present review, following a brief description of the major causes of AUB and dysmenorrhea, the molecular bases for the use of the LNG-IUS are summarized. This is followed by a compendium of its use in AUB and dysmenorrhea, concluding that the insertion of the system improves the quality of life, reduces menstrual blood loss better than other medical therapies, and decreases the extent of dysmenorrhea and pelvic pain. In addition, there is no evidence of a significant difference in these outcomes when the use of the LNG-IUS was compared with improvements offered by endometrial ablation or hysterectomy. Possibly, the most important mechanism of action of the system consists of its ability to induce amenorrhea, which effectively eliminates heavy bleeding and dysmenorrhea. However, no method is ideal for every woman, and, in the case of the LNG-IUS, younger age and severe dysmenorrhea seem to be associated with a higher risk of discontinuation. Conclusion: The higher-dose LNG-IUS is a useful tool for HMB and dysmenorrhea in women of all ages. The low cost and ease of use make the LNG-IUS an attractive option, especially when contraception is also desired.

show abstract